1. Cayman Islands Stocks

  2. •

    Distribution services

  3. •

    Medical distributors
Cowealth Medical Holding Co., Ltd.

Cowealth Medical Holding Co., Ltd.

TTPEX:4745
11.75
TWD
0.00
(0.00%)
-4.59EPS
943.64MMarket Cap
Cowealth Medical Holding Co., Ltd.
TPEX:4745
(Taipei Exchange)

Recent

price

11.75

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
16.13
23.89
32.61
34.09
42.47
41.13
37.16
37.98
49.06
60.23
60.97
66.36
72.65
62.14
54.13
38.17
38.22
Revenue per Share
0.17
0.83
2.7
3.61
4.21
4.36
2.2
2.17
3.6
3.61
1.61
1.8
1.22
0.63
0.01
-3.18
-3.27
Basic EPS, GAAP
0.61
0.63
3.38
-1.88
-0.41
-4.57
3.35
1.12
0.9
-3.04
10.03
-2
-3.8
-2.47
5.26
0.01
-7.52
Free Cash Flow per Basic Share
0.14
0.14
0.57
2.14
2.74
2.58
1.87
1.44
0.15
0.24
1.14
1.2
1.5
1.6
0.4
- -
- -
Dividend per Share
7
8.41
10.13
16.48
20.56
22.05
19.81
20.81
23.63
31.57
32.86
33.15
36.61
35.02
36.14
37.06
40.75
Book Value per Share
6.76
8.18
9.9
16.19
20.33
21.88
19.7
20.7
23.55
31.47
32.8
33.1
36.51
34.58
35.7
36.65
40.31
Tangible Book Value per Share
67
68
69
76
75
80
80
80
79
77
77
77
77
77
77
77
76
Basic Weighted Avg Shares
1,074
1,632
2,239
2,580
3,176
3,275
2,966
3,037
3,899
4,665
4,722
5,140
5,626
4,813
4,193
2,956
2,899
Sales/Revenue/Turnover
-0.72
2.18
9.45
12.59
12.89
7.57
9.85
8.19
9.19
9.47
8.6
7.2
6.93
5.06
2.17
-6.07
-5.54
Operating Margin (%)
25
35
42
46
55
61
82
123
103
94
108
70
57
55
51
50
48
Depreciation Expense
11
57
185
273
315
347
175
174
286
280
124
139
94
49
1
-247
-248
Net Income, GAAP
49.09
18.89
20.08
25.39
25.63
17.36
33.47
27.66
41.79
14.72
33.66
35.5
39.44
46.44
46.02
- -
- -
Effective Tax Rate (%)
1.06
3.47
8.27
10.58
9.92
10.6
5.91
5.72
7.34
6
2.63
2.71
1.67
1.02
0.02
-8.34
-8.56
Profit Margin (%)
415
282
388
697
1,290
1,093
1,305
1,211
1,574
2,865
2,896
3,004
4,497
4,089
4,195
3,538
3,326
Working Capital
14
21
- -
- -
201
- -
367
194
90
175
92
88
73
25
4
9
42
LT Debt
534
642
773
1,257
1,636
1,757
1,584
1,664
1,892
3,345
3,431
3,525
5,202
5,016
5,194
5,057
4,920
Total Equity
-0.57
3.31
17.04
20.92
17.75
8.65
7.31
6.68
6.93
9.02
4.79
4.93
4.2
2.39
0.91
- -
- -
Return on Invested Capital (%)
2.31
8.26
20.33
24.52
19.29
15.49
7.3
7.39
10.44
6.6
1.43
1.78
-0.6
-0.36
-0.53
- -
- -
Return on Capital (%)
2.14
9.63
26.18
26.89
21.77
20.45
10.5
10.69
16.38
13.09
4.99
5.46
3.48
1.77
0.02
-8.7
-9.63
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
999
1,221
1,319
LT Borrowings
9
23
41
LT Finance Leases
1
- -
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
77
77
66
Market Capitalization
1,963
1,444
944

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
5,513
5,502
5,549
Cash, Cash Equivalents & STI
1,136
948
636
Accounts Receivable, Net
3,157
3,291
3,317
Inventories
753
744
744
Total Current Liabilities
1,975
2,011
2,224
Payables & Accruals
- -
- -
- -
ST Debt
999
1,221
1,319
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.59%
9.53%
-2.65%
Free Cash Flow
-159.51%
-95.52%
-99.79%
Net Income, GAAP
-3,950.86%
-7,893.04%
-39,298.25%
Sales/Revenue/Turnover
0.37%
-7.7%
-29.49%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,046
1,084
1,038
1,024
4,193
2025
794
819
772
572
2,956
2026
702
854
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.07
-0.06
-0.08
0.08
0.01
2025
-0.39
-0.3
-0.41
-2.07
-3.18
2026
-0.4
-0.35
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.4
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
DataMeds AI, Inc. (NASDAQ:MEDS)
Selcuk Ecza Deposu Ticaret ve Sanayi A.S. (BIST:SELEC)
McKesson Corporation (NYSE:MCK)
Ibnsina Pharma (EGX:ISPH)
Cardinal Health, Inc. (NYSE:CAH)
Entero Healthcare Solutions Limited (NSE:ENTERO)
Business
Cowealth Medical Holding Co., Ltd. (4745.TWO) is a Taiwan-based holding company primarily engaged in the manufacture and distribution of medical devices and healthcare equipment. The company offers a range of products including disposable medical supplies such as syringes, infusion sets, and blood collection tubes; diagnostic equipment like blood glucose monitors and rapid test kits; wound care products including dressings and bandages; and surgical instruments encompassing scalpels, forceps, and disposable endoscopes. It also provides services related to medical device OEM/ODM production, regulatory compliance consulting for healthcare exports, and distribution logistics for medical consumables. Cowealth Medical operates primarily in Asia with expanding presence in Europe and North America, targeting hospitals, clinics, diagnostic laboratories, and pharmaceutical distributors. Founded in 2018 and headquartered in New Taipei City, Taiwan, the company serves key business segments in medical disposables, diagnostics, and healthcare logistics, with subsidiaries focused on manufacturing in China and sales offices in Southeast Asia. Its target markets include public health systems, private healthcare providers, and medical wholesalers seeking cost-effective, high-quality devices compliant with international standards such as ISO 13485 and CE marking. In the last two years, Cowealth Medical has pursued strategic expansions including a 2024 partnership with a leading European medical distributor to enhance market penetration in the EU; completion of a NT$500 million funding round in early 2025 to support new production lines for advanced diagnostic kits; and the launch of a branded line of AI-enabled remote patient monitoring devices in mid-2025. Additionally, the company acquired a stake in a Chinese wound care manufacturer in late 2024, bolstering its supply chain resilience, and announced a reorganization to streamline its OEM operations amid growing global demand for Taiwanese medical exports. These initiatives position Cowealth Medical for sustained growth in the competitive medtech sector.